Company profile
CureVac N.V.
Pipeline8 assets
- CVGBMCVGBM / tumor-associated antigens / unmodified mRNA cancer precision immunotherapy / Oncologynewly diagnosed surgically resected MGMT-unmethylated glioblastoma or astrocytoma with molecular signature of glioblastomaPhase 1ongoing
- sqNSCLC shared-antigen cancer precision immunotherapy candidateshared tumor antigens / unmodified mRNA cancer precision immunotherapy / Oncologysquamous non-small cell lung cancerIND/CTA filedIND and CTA submissions filed Q1 2025
- CV0601CV0601 / SARS-CoV-2 Omicron BA.4-5 spike antigen / mRNA vaccine / Infectious diseaseCOVID-19Phase 2study completed August 2024; GSK assumed full control
- CV0701CV0701 / SARS-CoV-2 Omicron BA.4-5 and original SARS-CoV-2 antigens / bivalent mRNA vaccine / Infectious diseaseCOVID-19Phase 2study completed August 2024; GSK assumed full control
- seasonal influenza mRNA vaccine candidateinfluenza antigens / multivalent mRNA vaccine / Infectious diseaseseasonal influenzaPhase 2GSK assumed full control
- avian influenza H5N1 mRNA vaccine candidateH5N1 influenza antigens / mRNA vaccine / Infectious diseaseavian influenza H5N1Phase 2GSK assumed full control
- COVID-19/influenza combination mRNA vaccine candidateSARS-CoV-2 and influenza antigens / combination mRNA vaccine / Infectious diseaseCOVID-19 and influenzaPhase 1/2GSK initiated study November 2024; GSK assumed full control
- UPEC FimH ferritin nanoparticle mRNA vaccine candidateFimH / mRNA vaccine / Infectious diseaseurinary tract infections caused by uropathogenic E. coliPreclinicallead candidate identified
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.